甘氨酸通过Nrf2通路改善慢性心力衰竭
Ruilei Zhang1, Hou Zhang2, Pengli Chen1
1Heart Center Ward 2, Anhui No. 2 Provincial People's Hospital, Hefei, People's Reupblic of China.
Clinical and experimental hypertension (New York, N.Y. : 1993)
|December 25, 2025
概括
甘氨酸 (GA) 通过增强NR3C1来对抗慢性心力衰竭 (CHF),NR3C1稳定了Nrf2. 这种机制减少了氧化应激,改善了心脏病模型中的心脏功能.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性心力衰竭 (CHF) 是一种复杂的疾病,其特点是心脏功能障碍和氧化应激增加.
- 甘酸 (GA) 是一种来自甘根的化合物,已显示出潜在的治疗益处.
- 基于GA对CHF影响的精确分子机制,特别是其与核受体和氧化应激通路的相互作用,需要进一步阐明.
研究的目的:
- 调查糖酸 (GA) 缓解慢性心力衰竭 (CHF) 的机制.
- 探索NR3C1调节Nrf2的作用及其对CHF环境中的氧化应激的影响.
- 为了确定GA是否增强NR3C1-介导的Nrf2.2稳定.
主要方法:
- 使用横向大动脉收缩建立CHF的老鼠模型,然后用GA或NR3C1敲击治疗.
- 在体外研究中,使用H9c2细胞接受异二醇来模仿CHF,治疗包括GA,Nrf2抑制剂或NR3C1调制.
- 评估心脏功能,缩,纤维化,氧化应激标志物 (ROS,GSH,MDA),线粒体膜潜力以及基因/蛋白质表达 (Nrf2,HO-1).
- 使用化酶,ChIP-qPCR和CHX试验检查NR3C1和Nrf2之间的调节相互作用.
主要成果:
- 在CHF大鼠模型中,GA治疗减轻了心肌缩和纤维化,并在CHF细胞模型中抑制了氧化应激.
- GA上调节了Nrf2及其下游目标HO-1蛋白水平.
- NR3C1被确定为Nrf2的关键上游调节器,增强其蛋白质稳定性.
- 抑制NR3C1降低了Nrf2和HO-1的表达,破坏了线粒体功能,并减弱了GA的保护作用.
结论:
- 甘氨酸 (GA) 通过一种涉及NR3C1-介导的Nrf2稳定机制来缓解慢性心力衰竭 (CHF).
- 这一途径有效地减少了氧化应激,为CHF提供了一种新的治疗策略.
- 准NR3C1-Nrf2轴为控制心力衰竭提供了一个有希望的途径.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
01:30Heart Failure V: Medical Management
195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
01:22Heart Failure Drugs: Diuretics
763
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
01:29Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:17Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K